Healthcare / Diagnostics & ResearchHKSE
$0.73
-0.05 (-6.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $246.2M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$427M
P/E
73.0x
↑EV/EBITDA
-4.7x
↓ROE
0.3%
↑Gross Margin
30.4%
↓Debt/Equity
0.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-45.7%
FCF CAGR
—
FCF margin
40.9%
FCF / Net income
84.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $601.4M · net income $2.9M · FCF $246.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $601.4M | $601.4M | $711.9M | $891.5M | $3.76B |
| Net Income | $2.9M | $2.9M | $-791.7M | $-102.3M | $377.3M |
| EBITDA | $85.1M | $85.1M | $-668.5M | $25.1M | $619.3M |
| EPS | — | — | -1.33 | -0.17 | 0.66 |
| Gross Margin | 30.4% | 30.4% | 29.6% | 36.5% | 34.8% |
| Operating Margin | -20.2% | -20.2% | -32.7% | -0.9% | 16.7% |
| Net Margin | 0.5% | 0.5% | -111.2% | -11.5% | 10.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.60 | 0.60 | 0.94 | 0.66 | 0.31 |
| Current Ratio | 1.59 | 1.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $246.2M | $246.2M | $228.4M | $271.6M | $-180.3M |
| Returns | |||||
| ROE | 0.3% | 0.3% | -69.2% | -4.8% | 14.9% |
| Valuation | |||||
| P/E | 73.00 | 73.00 | — | — | 24.06 |
| EV/EBITDA | -4.73 | -4.73 | — | 284.70 | 14.74 |
| P/B | 0.37 | 0.37 | 3.65 | 3.31 | 3.60 |
| Growth & Yield | |||||
| Revenue Growth | -15.5% | -15.5% | -20.1% | -76.3% | — |
| EPS Growth | — | — | -682.4% | -125.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-80.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.33 → n/d
Residual
-80.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.